G&E Herbal Biotechnology Co., Ltd. (TPEX:4911)
Taiwan · Delayed Price · Currency is TWD 28.70
-0.50 (-1.71%)
Aug 4, 2026, 1:30 PM CST
G&E Herbal Biotechnology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,829 | 2,734 | 3,339 | 3,440 | 2,972 | 1,558 | |
Market Cap Growth | -41.37% | -18.14% | -2.92% | 15.73% | 90.71% | -19.66% |
Enterprise Value | 1,408 | 2,323 | 3,017 | 3,226 | 2,849 | 1,446 |
Last Close Price | 28.70 | 38.41 | 46.24 | 47.15 | 40.74 | 21.36 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.84 | 19.64 | 32.72 | 47.51 | 402.69 | - |
PS Ratio | 7.00 | 8.84 | 13.41 | 18.96 | 46.01 | 63.43 |
PB Ratio | 1.94 | 2.95 | 4.01 | 4.51 | 4.30 | 2.28 |
P/TBV Ratio | 2.26 | 3.44 | 4.77 | 5.47 | 5.34 | 2.84 |
P/FCF Ratio | 242.03 | 40.82 | 25.94 | 31.86 | 30.64 | - |
P/OCF Ratio | 161.71 | 38.95 | 24.80 | 30.31 | 29.73 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.39 | 7.52 | 12.12 | 17.78 | 44.10 | 58.83 |
EV/EBITDA Ratio | 10.96 | 14.34 | 23.35 | 35.88 | 191.43 | - |
EV/EBIT Ratio | 11.95 | 15.25 | 25.22 | 39.98 | 519.39 | - |
EV/FCF Ratio | 186.30 | 34.69 | 23.44 | 29.88 | 29.37 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
Debt / EBITDA Ratio | 0.01 | 0.01 | 0.01 | 0.02 | - | - |
Debt / FCF Ratio | 0.09 | 0.01 | 0.01 | 0.02 | - | - |
Net Debt / Equity Ratio | -0.45 | -0.46 | -0.49 | -0.41 | -0.30 | -0.16 |
Net Debt / EBITDA Ratio | -3.30 | -2.65 | -3.15 | -3.46 | -13.84 | 10.65 |
Net Debt / FCF Ratio | -55.72 | -6.41 | -3.16 | -2.88 | -2.12 | 9.93 |
Asset Turnover | 0.26 | 0.32 | 0.27 | 0.22 | 0.09 | 0.04 |
Inventory Turnover | 1.66 | 1.95 | 1.96 | 1.55 | 1.14 | 0.81 |
Quick Ratio | 11.32 | 9.51 | 3.42 | 2.77 | 2.25 | 13.14 |
Current Ratio | 12.07 | 10.09 | 3.61 | 2.97 | 2.54 | 15.66 |
Return on Equity (ROE) | 12.97% | 15.80% | 12.78% | 9.96% | 1.07% | -2.87% |
Return on Assets (ROA) | 7.40% | 9.84% | 8.12% | 6.05% | 0.46% | -1.74% |
Return on Invested Capital (ROIC) | 21.90% | 28.94% | 22.28% | 13.78% | 1.04% | -3.38% |
Return on Capital Employed (ROCE) | 12.50% | 16.40% | 14.30% | 10.60% | 0.80% | -2.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.43% | 5.09% | 3.06% | 2.10% | 0.25% | -1.28% |
FCF Yield | 0.41% | 2.45% | 3.86% | 3.14% | 3.26% | -0.70% |
Dividend Yield | 3.70% | 2.81% | 1.52% | 0.98% | - | - |
Payout Ratio | 37.99% | 32.08% | 31.12% | - | - | - |
Buyback Yield / Dilution | -0.07% | -0.08% | -0.06% | -0.08% | - | - |
Total Shareholder Return | 3.61% | 2.73% | 1.46% | 0.89% | - | - |